Roth Capital Resumes Coverage on NovaBay Pharmaceuticals (NBY) at Buy
Tweet Send to a FriendGet Alerts NBY Hot Sheet
Price: $1.41 +0.71%
Rating Summary:
2 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
2 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade NBY Now!
Roth Capital resumes coverage on NovaBay Pharmaceuticals (NYSE: NBY) with a Buy. PT $3.50.
For an analyst ratings summary and ratings history on NovaBay Pharmaceuticals click here. For more ratings news on NovaBay Pharmaceuticals click here.
Shares of NovaBay Pharmaceuticals closed at $1.28 yesterday, with a 52 week range of $0.67-$2.35.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For an analyst ratings summary and ratings history on NovaBay Pharmaceuticals click here. For more ratings news on NovaBay Pharmaceuticals click here.
Shares of NovaBay Pharmaceuticals closed at $1.28 yesterday, with a 52 week range of $0.67-$2.35.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
- BTIG Starts Ambac Financial (AMBC) at Buy, Interesting Play with 'Optionality'
- Barclays Starts Verizon Communications (VZ) at Overweight
Create E-mail Alert Related Categories
New CoverageRelated Entities
Roth Capital
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
